Breast cancer incidence trends in Norway-explained by hormone therapy or mammographic screening?

International Journal of Cancer

Volumn 130, Issue 12, 2012, Pages 2930-2938

  Hofvind, Solveig ^a,b   Sakshaug, Solveig ^c   Ursin, Giske ^a,d,e   Graff Iversen, Sidsel ^c,f  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b OSLO METROPOLITAN UNIVERSITY   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF TROMSØ   (Norway)

Author keywords

breast cancer; hormone therapy; incidence; mammographic screening; Norway

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TIBOLONE; TRISEQUENS;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; DRUG MARKETING; DRUG UTILIZATION; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NORWAY; PRIORITY JOURNAL; TREND STUDY; VAGINA ATROPHY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; ESTROGEN REPLACEMENT THERAPY; FEMALE; GOVERNMENT PROGRAMS; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NORWAY; SURVIVAL RATE;

EID: 83155165559     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26280     Document Type: Article

References (47)

1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB,. Cancer incidence in five continents, vol. VIII. IARC Scientific Publication No 155. Lyon: IARC Press, 2002.
2. Krieger N, Löwy I, Aronowitz R, Bigby J, Dickersin K, Garner E, Gaudillière JP, Hinestrosa C, Hubbard R, Johnson PA, Missmer SA, Norsigian J, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health 2005; 59: 740-8.
3. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA,. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-74. (Pubitemid 46631679)
4. Glass AG, Lacey JV, Jr, Carreon JD, Hoover RN,. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1152-61. (Pubitemid 47233065)
5. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA,. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007; 99: 1335-9. (Pubitemid 47394172)
6. Fournier A, Berrino F, Clavel-Chapelon F,. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103-11. (Pubitemid 350179584)
7. Verkooijen HM, Koot VC, Fioretta G, van der Heiden M, Schipper ME, Rapiti E, Peeters PH, Peterse JL, Bouchardy C,. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 2008; 107: 389-95. (Pubitemid 351172106)
8. Lambe M, Wigertz A, Holmqvist M, Adolfsson J, Bardage C, Fornander T, Karlsson P, Odlind V, Persson I, Ahlgren J, Bergkvist L,. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 2010; 121: 679-83.
9. Bouchardy C, Usel M, Verkooijen HM, Fioretta G, Benhamou S, Neyroud-Caspar I, Schaffar R, Vlastos G, Wespi Y, Schäfer P, Rapiti E,. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat 2010; 12: 519-23.
10. Hentschel S, Heinz J, Schmid-Höpfner S, Obi N, Vettorazzi E, Chang-Claude J, Flesch-Janys D,. The impact of menopausal hormone therapy on the incidence of different breast cancer types-data from the Cancer Registry Hamburg 1991-2006. Cancer Epidemiol 2010; 34: 639-43.
11. Renard F, Vankrunkelsven P, Van EL, Henau K, Boniol M, Autier P,. Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 2010; 21: 2356-60.
12. von Euler-Chelpin M,. Breast cancer incidence and use of hormone therapy in Denmark 1978-2007. Cancer Causes Control 2011; 2: 181-7.
13. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J,; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. (Pubitemid 34761611)
14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-59.
15. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E,. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13. (Pubitemid 28502636)
16. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C,. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999; 10: 253-60. (Pubitemid 29358958)
17. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I,. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer 1999; 81: 339-44. (Pubitemid 29165190)
18. Colditz GA, Rosner B,. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000; 152: 950-64.
19. Rockhill B, Colditz GA, Rosner B,. Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol 2000; 151: 404-8. (Pubitemid 30463618)
20. Ross RK, Paganini-Hill A, Wan PC, Pike MC,. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-32. (Pubitemid 30117736)
21. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R,. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-91. (Pubitemid 30062864)
22. Ursin G, Tseng CC, Paganini-Hill A, Enger S, Wan PC, Formenti S, Pike MC, Ross RK,. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002; 20: 699-706. (Pubitemid 34111377)
23. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Berlin JA, et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol 2002; 100: 1148-58. (Pubitemid 35449180)
24. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243-53. (Pubitemid 37430077)
25. Olsson HL, Ingvar C, Bladstrom A,. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 97: 1387-92. (Pubitemid 36297767)
26. Colditz GA,. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 11 (2 Part 2): 2005; 909s-917s. (Pubitemid 40111105)
27. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D,; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66. (Pubitemid 34705519)
28. Pedersen AT, Iversen OE, Løkkegaard E, Mattsson LA, Milsom I, Nilsen ST, Ottesen B, Moen MH,. Impact of recent studies on attitudes and use of hormone therapy among Scandinavian gynaecologists. Acta Obstet Gynecol Scand 2007; 86: 1490-5. (Pubitemid 350135591)
29. Rønning M, (editor), Sakshaug S, Strøm H, Berg CL, Litleskare I, Blix HS,. Drug consumption in Norway 2005-2009. (Legemiddelforbruket i Norge 2005-2009). Oslo, Norway: Norwegian Institute of Public Health, 2010. ISBN 978-82-8082-398-4.
30. Bakken K, Lund E, Eggen AE,. The impact of hormone replacement therapy on the incidence of breast cancer in Norway. J Clin Oncol 2005; 23: 3636-7.
31. Hofvind S, Moller B, Thoresen S, Ursin G,. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 2006; 118: 3112-17.
32. Lee SA, Ross RK, Pike MC,. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005; 92: 2049-58. (Pubitemid 40897429)
33. Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Møller S, Rank F, Ottesen B, Lynge E,. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 2004; 91: 644-50. (Pubitemid 39141618)
34. Breen N, Yabroff KR, Meissner HI,. What proportion of breast cancers are detected by mammography in the United States? Cancer Detect Prev 2007; 31: 220-4. (Pubitemid 47260668)
35. Cronin KA, Ravdin PM, Edwards BK,. Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat 2009; 117: 223-4.
36. Hofvind S, Geller B, Vacek PM, Thoresen S, Skaane P,. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol 2007; 22: 447-55. (Pubitemid 47222954)
37. Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, Møller B,. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009; 45: 1218-31.
38. Diaz LK, Sneige N,. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005; 12: 10-19. (Pubitemid 40614485)
39. Widmark A, Olsen JB,. Mammografivirksomhet i Norge. Tekniske resultater. Report; StrålevernRapport 1995: 5. Osterås, Norway: Statens strålevern. In Norwegian.
40. Børretzen I, Lysdahl KB, Olerud HM,. Radiologi i Noreg-undersøkingsfrekvens per 2002, tidstrendar, geografisk variasjon og befolkningsdose Report: StrålevernRapport 2006: 6. Osterås, Norway: Statens strålevern. In Norwegian. ISSN 0804-4910.
41. Hofvind S, Sanderud A,. Report: use of mammography in Norway [Bruk av mammografi i Norge]. Oslo, Norway: Høgskolen I Oslo, 2010. HiO-rapport nr 14. In Norwegian. ISBN 978-82- 579-4735-4.
42. Perry N, Broeders M, deWolf C, Törnberg S, Holland R, von Karsa L,. European guidelines for quality assurance in breast cancer screening and diagnosis. Belgium: European Communities, 2006. ISBN:92-79-01258-4.
43. Boer R, Warmerdam P, de Koning H, van Oortmarssen G,. Extra incidence caused by mammographic screening. Lancet 1994; 343: 979. (Pubitemid 24117251)
44. Sprague BL, Trentham-Dietz A, Remington PL,. The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. Cancer Causes Control 2011; 22: 125-34.
45. Clarke CA, Glaser SL,. Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control 2007; 18: 847-52. (Pubitemid 47125116)
46. Skaane P,. Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. Acta Radiol 2009; 50: 3-14.
47. Holli K, Isola J, Cuzick J,. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998; 16: 3115-20. (Pubitemid 28417434)